DigestRedComo funciona
Red
/
Empresas
Sa
No verificado

Samsung Bioepis Co., Ltd.

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaSaludSanidad

18 Comunicados de prensa

Ver todos los comunicados de prensa
23/01/2026
Samsung Bioepis Releases First Quarter 2026 US Biosimilar Market Report, Providing Updates to Evolving Drug Pricing Models
Fuente
Samsung Bioepis Co., Ltd.
Editor
Business Wire
1.00
0
02/01/2026
Industria
Biotecnología
Farmacéutica
Óptica
Salud
Samsung Bioepis Begins Commercialization of BYOOVIZ®, Biosimilar to Lucentis (Ranibizumab), in Europe
Fuente
Samsung Bioepis Co., Ltd.
Editor
Business Wire
1.00
0
22/12/2025
Biotecnología
Farmacéutica
Salud
Sanidad
Industria
Samsung Bioepis Announces Approval of Ustekinumab Biosimilar in Japan
Fuente
Samsung Bioepis Co., Ltd.
Editor
Business Wire
1.00
0
02/12/2025
Biotecnología
Salud
Farmacéutica
Óptica
Industria
Pre-filled Syringe Presentation of BYOOVIZ®, Samsung Bioepis' Biosimilar to Lucentis (Ranibizumab), Gains European Approval
Fuente
Samsung Bioepis Co., Ltd.
Editor
Business Wire
1.00
0
01/12/2025
Industria
Biotecnología
Farmacéutica
Salud
Oncología
Samsung Bioepis Announces Launch of Denosumab Biosimilars, OBODENCE™ and XBRYK™, in Europe
Fuente
Samsung Bioepis Co., Ltd.
Editor
Business Wire
1.00
0
06/11/2025
Biotecnología
Farmacéutica
Salud
Sanidad
Mercado laboral
Industria
Samsung Bioepis Reaches Settlement Agreement for PYZCHIVA® (ustekinumab) in Europe
Fuente
Samsung Bioepis Co., Ltd.
Editor
Business Wire
1.00
0
29/10/2025
Mercado laboral
Industria
Salud
Ciencia
Farmacéutica
Óptica
Biotecnología
Samsung Bioepis to Commercialize BYOOVIZ® (ranibizumab) in Europe from January 2026
Fuente
Samsung Bioepis Co., Ltd.
Editor
Business Wire
1.00
0
23/10/2025
Biotecnología
Farmacéutica
Salud
Sanidad
Análisis de Mercados
Industria
Samsung Bioepis Releases Fourth Quarter 2025 US Biosimilar Market Report Providing Annual Biosimilar Trends and Future Market Trajectory
Fuente
Samsung Bioepis Co., Ltd.
Editor
Business Wire
1.00
0
20/10/2025
Samsung Bioepis And Phrontline Announce a Global Strategic Partnership to Advance Best-in-Class Antibody-Drug Conjugate Therapeutics for Solid Tumors
Fuente
Samsung Bioepis Co., Ltd.
Editor
Business Wire
1.00
0
21/07/2025
Biotecnología
Sanidad
Higiene alimentaria
Salud
Farmacéutica
Análisis de Mercados
Samsung Bioepis Releases Third Quarter 2025 US Biosimilar Market Report Exploring the Most-Favored-Nation (MFN) Policy and its Impact on Biosimilars
Fuente
Samsung Bioepis Co., Ltd.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0